Skip to main content
. 2023 Apr 29;15(9):2548. doi: 10.3390/cancers15092548

Table 3.

Blood, liver, and hepatoblastoma (HB) epigenotype results and CTNNB1 mutation status for BWS-HBs.

ID BWS Clinical Score BWS Blood Results BWS Liver
Results
BWS HB Results CTNNB1
Mutation
1 9 upd(11)pat upd(11)pat upd(11)pat c.101G>T, c.98C>T
2 10 upd(11)pat upd(11)pat upd(11)pat c.99_101dup
3 8 upd(11)pat \ upd(11)pat c. 65_100del
4 10 upd(11)pat \ \ c.100G>A
5 10 upd(11)pat \ \ \
6 10 upd(11)pat \ \ \
7 3 upd(11)pat \ \ \
8 12 IC2 LOM IC2 LOM IC2 LOM \
9 6 IC2 LOM IC2 LOM IC2 LOM c.85_102del
10 5 IC2 LOM IC2 LOM/IC1 GOM IC2 LOM/IC1 GOM c.122C>T
11 6 IC2 LOM \ \ \
12 10 IC2 LOM \ \ \
13 3 Normal \ IC2 LOM c.14-28_125del
14 2 \ IC1GOM upd(11)pat c.87_241+71del
15 4 Normal IC1 GOM upd(11)pat c.95A>T
16 6 Normal IC1 GOM upd(11)pat \

The table provides a summary of the blood, liver, and hepatoblastoma (HB) epigenotype results and the CTNNB1 mutation status for each BWS-HB. The BWS blood results for each patient are indicated and can include the following: upd(11)pat—paternal uniparental disomy of chromosome 11, IC2—loss of methylation at the KCNQ1OT1:TSS-DMR, IC2/IC1—partial loss of methylation at KCNQ1OT1:TSS-DMR and gain of methylation at H19/IGF2:IG-DMR, IC1—gain of methylation at the H19/IGF2:IG-DMR, and normal—no epigenetic abnormalities detected.